Dechra sees positive trading
The group, which has its Dales Pharmaceuticals manufacturing plant in Skipton, develops and makes drugs and food for animals through its pharmaceuticals arm, plus supplies drugs and services to the veterinary industry through its services arm.
Group revenue for the three months ended 31 March 2010 was 5.7 per cent ahead of last year. For the nine months ended 31 March 2010, revenue increased by 6.3 per cent over the corresponding period in the prior year.
Advertisement
Hide AdAdvertisement
Hide AdIn a statement, the company said there have been a number of advancements in its products.
Its flagship Vetoryl drug, which treats Cushings disease in dogs, has received approval for Japan, while Urilin, which treats urinary incontinence in dogs, has received approval in the EU.
Flexicam Injection, an extension to the group's canine pain relief range, has also received EU approval, while Equidone, its specialist equine product for the US market has completed safety and manufacturing checks.
In addition, it has secured the US marketing rights for Ovuplant, a specialist equine fertility drug which is currently marketed in Europe.
Advertisement
Hide AdAdvertisement
Hide AdThe group said: "Trading remains in line with the board's expectations and we remain confident that the group will continue to make good strategic progress throughout the remainder of the financial year."